174 Chapter 7 Neuroinflammation. Oct 14 2010;7(1):67. doi:10.1186/1742-2094-7-67 112. Goldberg SH, et al. CXCR3 expression in human central nervous system diseases. Neuropathol Appl Neurobiol. Apr 2001;27(2):127-38. doi:10.1046/ j.1365-2990.2001.00312.x 113. You T, et al. IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK/STAT signaling. Sci Rep. Mar 10 2017;7(1):41779. doi:10.1038/srep41779 114.Narcisse L, et al. The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes. Glia. Jan 15 2005;49(2):245-58. doi:10.1002/glia.20110 115. Zeis T, et al. The immunomodulatory oligodendrocyte. Brain Res. Jun 15 2016;1641(Pt A):139-148. doi:10.1016/j.brainres.2015.09.021 116. Choi JK, et al. GM-CSF reduces expression of chondroitin sulfate proteoglycan (CSPG) core proteins in TGF-beta-treated primary astrocytes. BMB Rep. Dec 2014;47(12):679-84. doi:10.5483/ bmbrep.2014.47.12.018 117. Boulay AC, et al. Immunoregulation at the gliovascular unit in the healthy brain: A focus on Connexin 43. Brain Behav Immun. Aug 2016;56:19. doi:10.1016/j.bbi.2015.11.017 118. Boulay AC, et al. Connexin 43 Controls the Astrocyte Immunoregulatory Phenotype. Brain sciences. Mar 22 2018;8(4):50. doi:10.3390/brainsci8040050 119. Allaman I, et al. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. Feb 2011;34(2):76-87. doi:10.1016/j. tins.2010.12.001 120. Choi SJ, et al. Differential expression, shedding, cytokine regulation and function of TNFR1 and TNFR2 in human fetal astrocytes. Yonsei Med J. Dec 31 2005;46(6):818-26. doi:10.3349/ ymj.2005.46.6.818 121. Kemanetzoglou E, et al. CNS Demyelination with TNF-alpha Blockers. Curr Neurol Neurosci Rep. Apr 2017;17(4):36. doi:10.1007/s11910-017-0742-1 122. Pegoretti V, et al. Selective Modulation of TNFTNFRs Signaling: Insights for Multiple Sclerosis Treatment. Front Immunol. 2018;9:925. doi:10.3389/fimmu.2018.00925 123.MiljkovicD,etal.Astrocytesinthetempestofmultiple sclerosis. FEBS Lett. Dec 1 2011;585(23):3781-8. doi:10.1016/j.febslet.2011.03.047 124. Burm SM, et al. Expression of IL-1beta in rhesus EAE and MS lesions is mainly induced in the CNS itself. J Neuroinflammation. Jun 6 2016;13(1):138. doi:10.1186/s12974-016-0605-8 125. Prins M, et al. Pathological differences between white and grey matter multiple sclerosis lesions. Ann N Y Acad Sci. Sep 2015;1351(1):99-113. doi:10.1111/nyas.12841 126. Sosunov A, et al. Alexander disease: an astrocytopathy that produces a leukodystrophy. Brain Pathol. May 2018;28(3):388-398. doi:10.1111/bpa.12601 127. Huang L, et al. Glial scar formation occurs in the human brain after ischemic stroke. Int J Med Sci. 2014;11(4):344-8. doi:10.7150/ijms.8140 128. Verkhratsky A, et al. Glia in the pathogenesis of neurodegenerative diseases. Biochem Soc Trans. Oct 2014;42(5):1291-301. doi:10.1042/ BST20140107 129. Anderson MA, et al. Heterogeneity of reactive astrocytes. Neurosci Lett. Apr 17 2014;565:23-9. doi:10.1016/j.neulet.2013.12.030 130. Rolls A, et al. The bright side of the glial scar in CNS repair. Nat Rev Neurosci. Mar 2009;10(3):235-41. doi:10.1038/nrn2591 131. Ceyzeriat K, et al. Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer’s disease. Acta Neuropathol Commun. Oct 16 2018;6(1):104. doi:10.1186/s40478-0180606-1 132. Ludwin SK, et al. Astrocytes in multiple sclerosis. Mult Scler. Aug 2016;22(9):1114-24. doi:10.1177/1352458516643396 133. Leibowitz SM, et al. NF-kappaB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications. Front Mol Neurosci. 2016/09/15 2016;9:84. doi:10.3389/ fnmol.2016.00084 134. Yi H, et al. IL-17A induces MIP-1alpha expression in primary astrocytes via Src/MAPK/PI3K/NF-kB pathways: implications for multiple sclerosis. J Neuroimmune Pharmacol. Dec 2014;9(5):629-41. doi:10.1007/s11481-014-9553-1 135. Brambilla R, et al. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J Immunol. Mar 1 2009;182(5):262840. doi:10.4049/jimmunol.0802954 136. Gonzalez-Reyes RE, et al. Involvement of Astrocytes in Alzheimer’s Disease from a Neuroinflammatory and Oxidative Stress Perspective. Front Mol Neurosci. 2017/12/19 2017;10:427. doi:10.3389/ fnmol.2017.00427 137.Ouali Alami N, et al. NF-kappaB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. EMBO J. Aug 15 2018;37(16):e98697. doi:10.15252/ embj.201798697 138. Butt AM, et al. Oligodendroglial Cells in Alzheimer’s Disease. Adv Exp Med Biol. 2019;1175:325-333. doi:10.1007/978-981-13-9913-8_12 139.Matute C, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci. Aug 29 2007;27(35):9525-33. doi:10.1523/ JNEUROSCI.0579-07.2007 140. Bezzi P, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by
RkJQdWJsaXNoZXIy MTk4NDMw